Gamida Cell ltd: Clinical Trials

7 trials sponsored by Gamida Cell ltd, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 terminated, 1 recruiting. 7 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Terminated 2, Recruiting 1
Phase 15Completed 3, Terminated 2

Follow Gamida Cell ltd: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Motixafortide for MRD Sensitization in AML
Motixafortide - Acute Myeloid Leukemia, Measurable Residual Disease
Phase 2RecruitingWashington University School of Medicine102026-07-232026-07-24
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
GDA-201 - Non-Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedGamida Cell ltd132022-07-052025-03-25
Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
CordIn - Sickle Cell Disease, Thalassemia
Phase 1 / Phase 2TerminatedGamida Cell ltd12016-04-042019-06-26
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
NiCord® - Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Phase 1 / Phase 2CompletedGamida Cell ltd362013-04-012020-10-22
Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
NiCord - Sickle Cell Disease & Thalassemia
Phase 1 / Phase 2CompletedGamida Cell ltd162012-09-012022-05-20
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
NiCord® - Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Phase 1 / Phase 2CompletedGamida Cell ltd122010-11-012021-08-03
Umbilical Cord Transplantation for the Elderly Population
StemEx - Hematologic Malignancies
Phase 2CompletedLoyola University182010-01-012019-08-21

Conditions studied

Hematologic Neoplasms (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Anemia, Sickle Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Myelodysplastic Syndromes (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Thalassemia (2)  ·  Genetic Diseases, Inborn (1)  ·  Hodgkin Disease (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Neoplasm, Residual (1)

Interventions

Niacinamide (1)

Countries

United States (7)  ·  France (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  Spain (1)

Top investigators

Joanne Kurtzberg, MD (2)  ·  Mitchell Horwitz, MD (2)  ·  Patrick Stiff, MD (2)  ·  Allistair Abraham, MD (1)  ·  David Snyder, PhD (1)  ·  Franco Locatelli, MD (1)  ·  Jean-Hugues Dalle, MD (1)  ·  Joel Brochstein, MD (1)  ·  Samuel Urrutia, MD (1)

Results publications

PMID 22198152, PMID 24911148, PMID 30523748, PMID 33560399